Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
96.62
+1.81 (1.91%)
Nov 21, 2024, 4:00 PM EST - Market closed
Blueprint Medicines Analyst Ratings
Total Analysts
19
Consensus Rating
Buy
Price Target
$120.79
Upside
+25.02%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $125 | Buy | Reiterates | $125 | +29.37% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +39.72% | Nov 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +39.72% | Nov 15, 2024 |
| JP Morgan | JP Morgan | Buy Initiates $126 | Buy | Initiates | $126 | +30.41% | Nov 14, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $153 → $151 | Buy | Maintains | $153 → $151 | +56.28% | Oct 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +39.72% | Oct 31, 2024 |
| Needham | Needham | Strong Buy Maintains $133 → $135 | Strong Buy | Maintains | $133 → $135 | +39.72% | Oct 31, 2024 |
| Needham | Needham | Strong Buy Reiterates $133 | Strong Buy | Reiterates | $133 | +37.65% | Oct 30, 2024 |
| UBS | UBS | Hold Initiates $88 | Hold | Initiates | $88 | -8.92% | Oct 24, 2024 |
| Needham | Needham | Strong Buy Maintains $130 → $133 | Strong Buy | Maintains | $130 → $133 | +37.65% | Aug 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $130 → $138 | Strong Buy | Maintains | $130 → $138 | +42.83% | Aug 2, 2024 |
| Baird | Baird | Buy Maintains $112 → $127 | Buy | Maintains | $112 → $127 | +31.44% | Aug 2, 2024 |
| Needham | Needham | Strong Buy Reiterates $130 | Strong Buy | Reiterates | $130 | +34.55% | Aug 1, 2024 |
| Barclays | Barclays | Hold Maintains $75 → $105 | Hold | Maintains | $75 → $105 | +8.67% | Jul 29, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $110 → $115 | Hold | Maintains | $110 → $115 | +19.02% | Jul 12, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $114 → $125 | Buy | Maintains | $114 → $125 | +29.37% | Jul 8, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.